Orthopediatrics CorpKIDS

OrthoPediatrics Corp reported $59.4 million in revenue for the quarter to 31 March 2026 but still managed to post a net loss of $10.7 million and an operating loss of $8.3 million, according to its latest 10-Q. Diluted EPS came in at negative forty-five cents on 23.7 million shares, while the company burned $3.3 million of operating cash and added another $1.8 million to fixed assets. The filing shows assets of $502.2 million against liabilities of $163.5 million, leaving shareholders’ equity at $338.7 million. Cash and equivalents fell to $12.2 million, with $36.6 million parked in short-term investments-about enough to keep the lights on, but not much of a war chest for aggressive expansion.

OrthoPediatrics designs and sells paediatric orthopaedic devices: plating systems for fractures, sports medicine implants for ACL and MPFL reconstructions, external fixation frames for limb correction, and a partnership with Pega Medical that adds a paediatric nail to the catalogue. The company’s product pages are glossy and detailed, featuring 3D renderings of titanium constructs meant to mend broken bones in children and adolescents. Yet the quarterly cash burn suggests the commercial flywheel is still grinding slowly, with inventory levels flat at $134 million and only a $139,000 decrease reported. The mismatch between the paediatric innovation story and the cash math is the real headline.

The 10-Q shows OrthoPediatrics spent $2.2 million on R&D in the quarter and $1.8 million on capex, while generating negative operating cash flow of $3.3 million. The company’s stockholders’ equity stands at $338.7 million, but the operating reality is closer to a break-even business with a growing inventory pile. The balance sheet remains healthy on paper-$502.2 million in assets versus $163.5 million in liabilities-but the income statement tells a different story. Diluted EPS of negative forty-five cents is not the kind of metric that attracts growth capital without a credible path to profitability.

For context on the product pipeline, OrthoPediatrics’ trauma portfolio includes the Pediatric Plating Platform™ for hip trauma, while the sports medicine line features ACL and MPFL reconstruction systems. The external fixation division, the newest addition, offers mini, micro, and monorail fixators in a range of sizes. The company’s partnership with Pega Medical brings the GAP™ Nail to the catalogue, a 3D-rendered device intended for paediatric long-bone fractures. The images are impressive; the cash flow, less so. The SEC filing index for OrthoPediatrics can be found here: https://www.sec.gov/edgar/browse/?CIK=1425450.

The company’s latest SEC submissions JSON shows routine 8-Ks and 10-Q filings but no material news releases in the review window. The companyfacts JSON on EDGAR confirms key line items like revenue, net income, EPS, and cash used in operations, but it does not reveal customer counts, hospital contracts, or geographic breakdowns. The filing rail is transparent on financials; the operating narrative remains thin. Investors looking for segment-level profitability, hospital adoption rates, or payer mix will need to dig beyond the 10-Q. The SEC companyfacts endpoint is here: https://data.sec.gov/api/xbrl/companyfacts/CIK0001425450.json.

The operating cash outflow of $3.3 million and the modest capex run-rate of $1.8 million suggest OrthoPediatrics is still in a capital-efficient but cash-burning phase. The inventory build to $134 million implies inventory is turning slowly, which could reflect cautious production planning, supply-chain buffering, or slower-than-expected hospital adoption. Without segment-level disclosures or hospital roll-out data, the filing rail does not prove demand is accelerating. The source rail leaves the operating narrative under-specified; the balance sheet is clear, but the business flywheel is not.